ATE521701T1 - Verbesserte konstrukte zur expression lysosomaler polypeptide - Google Patents

Verbesserte konstrukte zur expression lysosomaler polypeptide

Info

Publication number
ATE521701T1
ATE521701T1 AT04704039T AT04704039T ATE521701T1 AT E521701 T1 ATE521701 T1 AT E521701T1 AT 04704039 T AT04704039 T AT 04704039T AT 04704039 T AT04704039 T AT 04704039T AT E521701 T1 ATE521701 T1 AT E521701T1
Authority
AT
Austria
Prior art keywords
gaa
lysosomal
utr
isolated nucleic
polypeptide
Prior art date
Application number
AT04704039T
Other languages
English (en)
Inventor
Dwight Koeberl
Baodong Sun
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Application granted granted Critical
Publication of ATE521701T1 publication Critical patent/ATE521701T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT04704039T 2003-01-22 2004-01-21 Verbesserte konstrukte zur expression lysosomaler polypeptide ATE521701T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44178903P 2003-01-22 2003-01-22
PCT/US2004/001453 WO2004064750A2 (en) 2003-01-22 2004-01-21 Improved constructs for expressing lysosomal polypeptides

Publications (1)

Publication Number Publication Date
ATE521701T1 true ATE521701T1 (de) 2011-09-15

Family

ID=32771976

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04704039T ATE521701T1 (de) 2003-01-22 2004-01-21 Verbesserte konstrukte zur expression lysosomaler polypeptide

Country Status (7)

Country Link
US (3) US20040248262A1 (de)
EP (1) EP1587923B1 (de)
JP (1) JP5433133B2 (de)
AT (1) ATE521701T1 (de)
ES (1) ES2371913T3 (de)
PT (1) PT1587923E (de)
WO (1) WO2004064750A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
CA2445577C (en) * 2001-04-30 2012-07-03 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2005078077A2 (en) * 2004-02-10 2005-08-25 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
EP1904638A2 (de) * 2005-07-18 2008-04-02 Metabogal Ltd. Mukosale oder enterale verabreichung biologisch aktiver makromoleküle
FR2889066B1 (fr) * 2005-07-28 2007-11-09 Centre Nat Rech Scient Procede d'immunisation genetique par electrotransfert contre une toxine et antiserum susceptible d'etre obtenu par ledit procede
JP2010509344A (ja) * 2006-11-13 2010-03-25 ザイストール セラピューティクス， インコーポレイテッド ポンペ病を治療するための方法
US20120322861A1 (en) * 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
DK2279210T3 (en) 2008-05-07 2017-07-24 Biomarin Pharm Inc Lysosomal targeting peptides and uses thereof
US20110318322A1 (en) 2009-01-12 2011-12-29 Nektar Therapeutics Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer
ES2398006T3 (es) * 2009-02-04 2013-03-13 Stryker Leibinger Gmbh & Co. Kg Herramienta quirúrgica eléctrica y conjunto de accionamiento para la misma
ES2405550T3 (es) * 2009-02-04 2013-05-31 Stryker Leibinger Gmbh & Co. Kg Herramienta eléctrica quirúrgica, procedimiento de funcionamiento y grupo constructivo de accionamiento correspondientes
ES2569514T3 (es) 2009-06-17 2016-05-11 Biomarin Pharmaceutical Inc. Formulaciones para enzimas lisosómicas
JP6045492B2 (ja) 2010-06-25 2016-12-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物
NZ605871A (en) 2010-06-25 2015-02-27 Shire Human Genetic Therapies Treatment of sanfilippo syndrome type b
DK2585104T3 (da) 2010-06-25 2019-10-14 Shire Human Genetic Therapies Fremgangsmåder og sammensætninger tilcns-levering af arylsulfatase a
DK3103469T3 (en) 2010-06-25 2021-02-22 Shire Human Genetic Therapies Indgivelse af terapeutiske midler til centralnervesystemet
JP6073783B2 (ja) 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
IL291554B2 (en) 2010-06-25 2024-02-01 Shire Human Genetic Therapies Administering therapeutic agents to the central nervous system
WO2012085622A1 (en) 2010-12-22 2012-06-28 Fondazione Telethon Therapeutic strategies to treat cns pathology in mucopolysaccharidoses
WO2012145644A1 (en) * 2011-04-22 2012-10-26 Genzyme Corporation Modified acid alpha glucosidase with accelerated processing
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
DK2753346T3 (da) 2011-09-07 2020-05-25 Sinai School Medicine Ceramidase og celledifferentiering
JP6329483B2 (ja) 2011-10-12 2018-05-23 シナジェバ・バイオファーマ・コーポレイションＳｙｎａｇｅｖａ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐ． 組換えヒトｎａｇｌｕタンパク質およびその利用
EP2793922B1 (de) 2011-12-23 2019-10-30 Shire Human Genetic Therapies, Inc. Stabile formulierungen zur verabreichung von arylsulfatase a in das zns
HUE051020T2 (hu) 2012-06-01 2021-01-28 Icahn School Med Mount Sinai A ceramid szintjei a fertõzések kezelésében és megelõzésében
MX2014015985A (es) 2012-06-19 2015-07-21 Univ Florida Composiciones y metodos para tratar enfermedades.
AU2014218854B2 (en) 2013-02-20 2019-01-24 Valerion Therapeutics, Llc Methods and compositions for treatment of Pompe disease
ES2739811T3 (es) 2013-03-14 2020-02-04 Icahn School Med Mount Sinai Composiciones terapéuticas de ceramidasa ácida y métodos de fabricación y uso de ellas
WO2016149508A1 (en) 2015-03-19 2016-09-22 Shire Human Genetic Therapies, Inc. Mrna therapy for pompe disease
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
EP3293260A1 (de) 2016-09-12 2018-03-14 Genethon Saure alpha-glucosidase-varianten und verwendungen davon
EP3510149A1 (de) * 2016-09-12 2019-07-17 Genethon Saure alpha-glucosidase-varianten und verwendungen davon
EP3293203A1 (de) 2016-09-12 2018-03-14 Genethon Saure alpha-glucosidase-varianten und verwendungen davon
EP3293259A1 (de) * 2016-09-12 2018-03-14 Genethon Saure alpha-glucosidase-varianten und verwendungen davon
US11160493B2 (en) * 2017-03-03 2021-11-02 Musclesound, Inc. System and method for determining a subject's muscle fuel level, muscle fuel rating, and muscle energy status
BR112019025888A2 (pt) 2017-06-07 2020-06-30 Regeneron Pharmaceuticals, Inc. polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica
BR112020021962A2 (pt) 2018-04-30 2021-01-26 Amicus Therapeutics, Inc. construtos para terapia gênica e métodos de uso
CA3115944A1 (en) 2018-10-10 2020-04-16 Amicus Therapeutics, Inc. Disulfide bond stabilized polypeptide compositions and methods of use
CN113677800A (zh) * 2018-11-13 2021-11-19 索元生物医药(美国)有限公司 包含用于结合结构域和可分泌肽的基因的重组载体
WO2020102645A1 (en) * 2018-11-16 2020-05-22 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus for treating pompe disease
WO2020102667A2 (en) * 2018-11-16 2020-05-22 Asklepios Biopharmaceutical, Inc. Vectors comprising a nucleic acid encoding lysosomal enzymes fused to a lysosomal targeting sequence
BR112021021792A2 (pt) * 2019-04-30 2022-01-04 Amicus Therapeutics Inc Composições úteis para tratamento de doença de pompe
WO2021078834A1 (en) 2019-10-22 2021-04-29 Genethon Chimeric acid-alpha glucosidase polypeptides and uses thereof
WO2021078833A1 (en) 2019-10-22 2021-04-29 Genethon Chimeric polypeptides and uses thereof
WO2021102107A1 (en) * 2019-11-19 2021-05-27 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders
US20230321237A1 (en) * 2020-08-13 2023-10-12 Epivax, Inc. Regulatory t cell epitopes
CA3236188A1 (en) * 2021-10-27 2023-05-04 The University Of North Carolina At Chapel Hill Aav-idua vector for treatment of mps i
TW202403048A (zh) * 2022-03-18 2024-01-16 美商艾司科皮歐斯生物製藥有限公司 用於治療龐貝症之具有訊號肽修飾之以密碼子最佳化核酸編碼α-葡萄糖苷酶(GAA)之治療性腺相關病毒

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4407956A (en) 1981-03-13 1983-10-04 The Regents Of The University Of California Cloned cauliflower mosaic virus DNA as a plant vehicle
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
DE3432718C1 (de) 1984-09-06 1986-05-22 Biotest Pharma GmbH, 6000 Frankfurt Verfahren zur Herstellung einer Loesung von Milch- und/oder Kolostralimmunglobulinen
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
JP2627899B2 (ja) 1987-08-19 1997-07-09 株式会社 ビタミン研究所 遺伝子封入リポソームの製法
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
US5231020A (en) 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
ATE154362T1 (de) * 1989-09-05 1997-06-15 Biotech Australia Pty Ltd Verfahren zur herstellung von pai-2
AU625013B2 (en) 1989-11-03 1992-06-25 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5225341A (en) 1990-07-19 1993-07-06 The Regents Of The University Of California Biologically safe plant transformation system using a ds transposon
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5339346A (en) 1993-05-20 1994-08-16 At&T Bell Laboratories Device fabrication entailing plasma-derived x-ray delineation
US5837484A (en) 1993-11-09 1998-11-17 Medical College Of Ohio Stable cell lines capable of expressing the adeno-associated virus replication gene
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5623054A (en) 1994-06-23 1997-04-22 The General Hospital Corporation Crucifer AFT proteins and uses thereof
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6110456A (en) 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
US6118045A (en) * 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US5962313A (en) * 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
AU4424497A (en) * 1996-09-13 1998-04-02 Transkaryotic Therapies, Inc. Therapy for alpha-galactosidase a deficiency
CA2271325A1 (en) 1996-11-12 1998-05-22 The Regents Of The University Of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
AU5603998A (en) 1996-12-18 1998-07-15 Targeted Genetics Corporation Recombinase-activatable AAV packaging cassettes for use in the production of AV vectors
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
US6251677B1 (en) 1997-08-25 2001-06-26 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
AU764686B2 (en) 1998-08-28 2003-08-28 Duke University Adenoviruses deleted in the IVa2, 100K, polymerase and/or preterminal protein sequences
US6858425B1 (en) * 1998-12-04 2005-02-22 Genzyme Corporation Human acid alpha glucosidase gene and bovine alpha-S1 casein gene sequences
KR20010101131A (ko) * 1998-12-07 2001-11-14 추후기재 폼페병의 치료 방법
US6387368B1 (en) 1999-02-08 2002-05-14 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
DK1151102T3 (da) 1999-02-12 2006-05-29 Amgen Inc Glycosylerede leptinpræparater og relaterede fremgangsmåder
WO2001036603A2 (en) 1999-11-17 2001-05-25 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
ES2799882T3 (es) * 2000-07-18 2020-12-22 Univ Duke Tratamiento de glucogenosis de tipo II
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
CA2445577C (en) * 2001-04-30 2012-07-03 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US6946126B2 (en) * 2001-06-04 2005-09-20 Duke University Replicating adenovirus vectors
AU2003223766A1 (en) 2002-04-30 2003-11-17 University Of North Carolina At Chapel Hill Secretion signal vectors
US7858367B2 (en) 2002-04-30 2010-12-28 Duke University Viral vectors and methods for producing and using the same
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine

Also Published As

Publication number Publication date
EP1587923B1 (de) 2011-08-24
WO2004064750A3 (en) 2004-11-11
ES2371913T3 (es) 2012-01-11
JP2006517404A (ja) 2006-07-27
US9873868B2 (en) 2018-01-23
US20180371440A1 (en) 2018-12-27
US20040248262A1 (en) 2004-12-09
WO2004064750A2 (en) 2004-08-05
JP5433133B2 (ja) 2014-03-05
EP1587923A2 (de) 2005-10-26
PT1587923E (pt) 2011-12-07
US20120276072A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
ATE521701T1 (de) Verbesserte konstrukte zur expression lysosomaler polypeptide
DK1240325T3 (da) IL-17 og IL-17R homologe polypeptider og terapeutisk anvendelse deraf
DE602006011574D1 (de) Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
DK1623990T3 (da) Sammensætninger og fremgangsmåder til tumorbehandling
ATE397061T1 (de) Verfahren zur herstellung von proteinen
ATE444971T1 (de) Zusammensetzungen und verfahren für die tumor- behandlung
DE60026733D1 (de) Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung
WO2001087978A3 (en) Human abc transporter and its use
MXPA04004561A (es) Distribuidor de aire para sistema de biolixiviacion.
ES2264700T3 (es) Preparacion de una proteina recombinante en una celula huesped procariotica mediante el uso de un codon mejorado.
ATE452137T1 (de) Verfahren und konstrukte zur expression von clostripain mit hoher ausbeute
EP1239051A3 (de) Humanes POSH-ähnliches Protein
EP1281758A3 (de) Vier menschliche Zinc-Finger Proteine: MDZ3, MDZ4, MDZ7 und MDZ12
DE60137222D1 (de) Humanes trp-ähnliches kalziumkanalprotein-2 tlcc-2
ATE346926T1 (de) Menschliche twik-8 moleküle und ihre verwendung
DE60225046D1 (de) Produktion eukaryontischer proteine und nukleinsäuremoleküle in c. elegans
HUP0402045A2 (hu) Az ee3-proteincsalád és az azokat kódoló DNS-szekvenciák
DE60011464D1 (de) Herstellung von heterloge proteine
WO2003037931A3 (en) Human angiomotin-like protein 1
DE60234047D1 (de) 15603, ein mitglied der humanen ionenkanal-familie
ATE415422T1 (de) Menschliches gas-6 (growth arrest-specific gene 6) protein und dafür kodierende nukleinsäuren
EP1243660A3 (de) Human-UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10
WO2002026818A3 (en) Human nedd-1
EP1229046A3 (de) Humanes patched-ähnliches Protein, dass in Testis exprimiert ist
EP1229132A3 (de) Humanes RALGDS-ähnliches Protein 3

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties